Início › Leucemia Linfocítica Crônica › Maryland
Ensaios clínicos de Leucemia Linfocítica Crônica em Maryland
23 estudos para Leucemia Linfocítica Crônica estão buscando participantes em locais em Maryland.
Cidades em Maryland
Texto oficial do estudo (Inglês)
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
- National Institutes of Health Clinical Center, Bethesda
RecrutandoEstudo observacional
Idades de 18 a 110 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05724121Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- e mais 10
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 111, Bethesda
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- The University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- American Oncology Partners of Maryland Pa, Bethesda
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05006716A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- American Oncology Partners of Maryland Pa, Bethesda
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06846671Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
- National Institutes of Health Clinical Center, Bethesda
RecrutandoEstudo observacional
Idades de 18 a 110 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT00923507Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- National Institutes of Health Clinical Center, Bethesda
RecrutandoFase 2
Idades de 18 a 85 · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT03986034A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Center for Cancer and Blood Disorders ( Site 5439), Bethesda
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT05947851Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
- National Institutes of Health Clinical Center, Bethesda
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT01087333Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Johns Hopkins Asthma & Allergy Center, Baltimore
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Maryland Oncology Hematology, Silver Spring
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07221500Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Maryland, Baltimore
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT03666000Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
- National Institutes of Health Clinical Center, Bethesda
RecrutandoFase 1 inicial
Idades de 18 a 100 · Todos os sexos · Atualizado em 21 de ago. de 2026 · NCT07428707A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- American Oncology Partners of Maryland, PA, Bethesda
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT05254743ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- The Center for Cancer and Blood Disorders-Bethesda, Bethesda
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT07342478Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
- National Institutes of Health Clinical Center, Bethesda
RecrutandoFase 1/2
Idades de 18 a 120 · Todos os sexos · Atualizado em 16 de jul. de 2026 · NCT06364423A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institute of Health, Bethesda
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de jul. de 2026 · NCT05131022A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- American Oncology Partners, PA, Bethesda
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 19 de mai. de 2026 · NCT06588478A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 266445, Bethesda
- Maryland Oncology Hematology - Silver Spring /ID# 267557, Silver Spring
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 9 de abr. de 2026 · NCT06428019A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 20 de mar. de 2026 · NCT04830137AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center, Baltimore
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 10 de dez. de 2025 · NCT05602363Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.